CARMUSTINE
ALK-Negative Anaplastic Large Cell Lymphoma
University of NebraskaSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the ALK-Negative Anaplastic Large Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
PREDNISONE TABLETS Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
Inno-206 City of Hope Medical Center | Phase 4 | BB |
ETOPOSIDE City of Hope Medical Center | Phase 4 | BB |
Ifosfamide Shandong Provincial Hospital | Phase 4 | BB |
View all 26 →
Same molecule, other indications
CARMUSTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →